Liquidia (NASDAQ:LQDA – Get Free Report)‘s stock had its “buy” rating affirmed by investment analysts at Needham & Company LLC in a report issued Thursday, Benzinga reports. They currently have a $28.00 price target on the stock. Needham & Company LLC’s price target would indicate a potential upside of 152.71% from the stock’s previous close.

A number of other equities analysts have also weighed in on LQDA recently. Oppenheimer initiated coverage on Liquidia in a report on Tuesday, June 25th. They gave the company a “market perform” rating. HC Wainwright affirmed a “buy” rating and set a $32.00 price target on shares of Liquidia in a research note on Wednesday, July 10th. One research analyst has rated the stock with a sell rating, one has given a hold rating, and four have given a buy rating to the stock. According to data from MarketBeat.com, Liquidia currently has an average rating of “Moderate Buy” and an average price target of $21.60.

Get our latest research report on LQDA

Liquidia Price Development

NASDAQ:LQDA opened at $11.08 on Thursday. The company’s 50-day moving average is $12.66 and its 200-day moving average is $13.42. The company has a market cap of $846.67 million, a price-to-earnings ratio of -7.10, and a beta of 0.32. Liquidia has a 1-year low of $5.71 and a 1-year high of $16.99.

Liquidia (NASDAQ:LQDA – Get Free Report) issued its quarterly earnings results on Monday, May 13. The company reported ($0.54) EPS for the quarter, which missed analysts’ consensus estimates of ($0.32) by ($0.22). The company had revenue of $2.97 million during the quarter, compared to analyst estimates of $4.31 million. Liquidia had a negative net margin of 674.42% and a negative return on equity of 177.83%. As a group, equities analysts expect Liquidia to post -1.32 EPS for the current fiscal year.

Insider activity

In related news, CFO Michael Kaseta sold 3,906 shares of the company’s stock in a transaction dated Friday, July 12. The shares were sold at an average price of $12.53, for a total transaction of $48,942.18. Following the transaction, the chief financial officer now owns 312,389 shares of the company’s stock, valued at approximately $3,914,234.17. The transaction was disclosed in a filing with the SEC, available at this hyperlink. In other news, CEO Roger Jeffs sold 8,053 shares of the company’s stock in a transaction that occurred on Friday, July 12. The shares were sold at an average price of $12.53, for a total value of $100,904.09. Following the completion of the transaction, the chief executive officer now owns 818,932 shares of the company’s stock, valued at $10,261,217.96. The transaction was disclosed in a legal document filed with the SEC, available on the SEC’s website. Also, CFO Michael Kaseta sold 3,906 shares of the company’s stock in a transaction that occurred on Friday, July 12th. The shares were sold at an average price of $12.53, for a total transaction of $48,942.18. Following the sale, the chief financial officer now directly owns 312,389 shares of the company’s stock, valued at $3,914,234.17. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 17,731 shares of the company’s stock valued at $226,733. 31.60% of the shares are currently held by corporate insiders.

Hedge funds weigh Liquidia

Several institutional investors have recently modified their holdings of the company. American International Group Inc. increased its holdings in Liquidia by 5.2% in the first quarter. American International Group Inc. now owns 24,806 shares of the company’s stock worth $366,000 after purchasing an additional 1,215 shares during the period. Bleakley Financial Group LLC increased its position in Liquidia by 6.6% in the first quarter. Bleakley Financial Group LLC now owns 33,250 shares of the company’s stock worth $490,000 after purchasing an additional 2,057 shares in the last quarter. Fortitude Family Office LLC purchased a new position in shares of Liquidia in the fourth quarter worth approximately $26,000. SG Americas Securities LLC increased its position in shares of Liquidia by 17.4% during the fourth quarter. SG Americas Securities LLC now owns 15,540 shares of the company’s stock worth $187,000 after purchasing an additional 2,298 shares in the last quarter. Finally, Hilltop National Bank bought a new stake in shares of Liquidia during the second quarter worth about $33,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

About Liquidia

(Get free report)

Liquidia Corporation, a biopharmaceutical company, develops, manufactures and markets several products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Also see

Get news and reviews for Liquidia Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Liquidia and related companies with MarketBeat.com’s FREE daily email newsletter.